Our top pick for
OrganiGram Holdings Inc is a drug manufacturers-specialty & generic business based in the US. OrganiGram shares (OGI) are listed on the NASDAQ and all prices are listed in US Dollars. OrganiGram employs 517 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.32|
|52-week range||$1.07 - $6.45|
|50-day moving average||$2.36|
|200-day moving average||$2.64|
|Wall St. target price||$2.85|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-2.52%|
|1 month (2021-09-23)||N/A|
|3 months (2021-07-27)||-5.69%|
|6 months (2021-04-27)||-11.45%|
|1 year (2020-10-27)||90.16%|
|2 years (2019-10-25)||-38.46%|
|3 years (2018-10-26)||4.39|
|5 years (2016-10-27)||14.29%|
|Revenue TTM||$74.7 million|
|Gross profit TTM||$-50,395,000|
|Return on assets TTM||-13.83%|
|Return on equity TTM||-34.81%|
|Market capitalisation||$699.2 million|
TTM: trailing 12 months
There are currently 14.2 million OrganiGram shares held short by investors – that's known as OrganiGram's "short interest". This figure is 10.8% down from 15.9 million last month.
There are a few different ways that this level of interest in shorting OrganiGram shares can be evaluated.
OrganiGram's "short interest ratio" (SIR) is the quantity of OrganiGram shares currently shorted divided by the average quantity of OrganiGram shares traded daily (recently around 5.0 million). OrganiGram's SIR currently stands at 2.82. In other words for every 100,000 OrganiGram shares traded daily on the market, roughly 2820 shares are currently held short.
However OrganiGram's short interest can also be evaluated against the total number of OrganiGram shares, or, against the total number of tradable OrganiGram shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OrganiGram's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 OrganiGram shares in existence, roughly 50 shares are currently held short) or 0.0592% of the tradable shares (for every 100,000 tradable OrganiGram shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OrganiGram.
Find out more about how you can short OrganiGram stock.
We're not expecting OrganiGram to pay a dividend over the next 12 months.
OrganiGram's shares were split on a 67:1 basis on 27 January 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 67 shares. This wouldn't directly have changed the overall worth of your OrganiGram shares – just the quantity. However, indirectly, the new 98.5% lower share price could have impacted the market appetite for OrganiGram shares which in turn could have impacted OrganiGram's share price.
Over the last 12 months, OrganiGram's shares have ranged in value from as little as $1.07 up to $6.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OrganiGram's is 1.2083. This would suggest that OrganiGram's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Organigram Holdings Inc. , through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co. , ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.